Brief: Innate Pharma 9-Month Revenue Down At 10.3 Million Euros

Innate Pharma SA

16/11/2021 06:35

Nov 16 (Reuters) - Innate Pharma SA  IPH.PA :
    * INNATE PHARMA Q3 2021 REPORT
    * CASH POSITION OF EUR 141.8 MILLION AS OF SEPTEMBER 30,
2021
    * PRE-CLINICAL DATA PRESENTED AT SITC WITH SANOFI FROM LEAD
NEXT-GENERATION NK CELL ENGAGER PLATFORM, ANKET™ TARGETING CD123
IN ACUTE MYELOID LEUKEMIA
    * REVENUES FOR FIRST NINE MONTHS OF 2021 AMOUNTED TO EUR
10.3
MILLION (EUR 33.6 MILLION FOR SAME PERIOD IN 2020)
    * COMPANY IS INITIATING AN INVESTIGATOR-SPONSORED PHASE 1
TRIAL OF
IPH5301 IN COLLABORATION WITH INSTITUT PAOLI-CALMETTES
    * ASTRAZENECA IS CONDUCTING A PHASE 1 TRIAL IN SOLID TUMORS
WITH
IPH5201 ALONE OR IN COMBINATION WITH DURVALUMAB. DATA IS
EXPECTED TO BE PRESENTED IN 2022

Source text for Eikon:  ID:nBw93LJ4Va 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))